Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMMUF0O)

Drug Name
AZD8630 Drug Info
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMMUF0O

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Thymic stromal lymphopoietin (TSLP) TTHMW3T TSLP_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 12 Disease of the respiratory system
Disease Class ICD-11: CA23 Asthma
The Studied Tissue Nasal and bronchial airway
The Studied Disease Asthma [ICD-11:CA23]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Thymic stromal lymphopoietin (TSLP) DTT TSLP 8.89E-01 0.3 0.26
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT05110976) Phase I, Randomised, Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8630 in Healthy Adult Subjects (Part A) and Adults With Asthma on Medium to High Dose Inhaled Corticosteroids and Long-acting Beta-agonists (Part B). U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of AstraZeneca